One common treatment for those with HER2-positive breast ... The mutation causes the gene to produce too many HER2/neu proteins (or just HER2 proteins). In normal amounts, these proteins act ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

The EMBER-3 study introduced imlunestrant, an oral selective estrogen receptor degrader (SERD), as a potential treatment for hormone receptor–positive, HER2-negative metastatic breast cancer ...

5,6 This test is for patients who have recently been diagnosed with node-negative or node-positive HR+ and HER2- invasive breast ... your tumor might respond to treatment.

and human epidermal growth factor receptor 2 (HER2/neu)—that targeted medications act upon to reduce tumor growth. Even when initial treatment leads to remission, the chance of triple-negative ...

The NCCN Guidelines Category of Preference is designated as “useful in certain circumstances” as a treatment option for patients with HER2-mutated tumors. This addition was based on results ...